Going direct: notes on Eli Lilly at a trillion | Alex’s blog

Personal site for posts about my interests: the biotech industry, medicine, molecular biology, neuroscience, biorisk, science, consciousness, AI, innovation, decision making, philosophy, games, sci-fi, probability, and forecasting (among other things). I write to learn, mostly about biotech.

A few weeks ago, Eli Lilly CEO Dave Ricks appeared on Stripe’s “Cheeky Pint” podcast . It’s rare 1 for pharma executives to make unscripted media appearances (the industry is risk averse by nature), so seeing one sit down with the Collison brothers — on a tech podcast, no less — is notable. Pharma’s deliberate distance 2 has come at a cost: the industry has mostly failed to establish positive relationships with consumers. Tech, by contrast, consistently ranks as one of the most liked industries; pharma is one of the most disliked . Tech CEOs are household names, yet hardly anyone outside the i

related reading

• Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharmacheekypint.substack.com
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• Interview: Patrick Collison, co-founder and CEO of Stripenoahpinion.substack.com
• Tech vs Biotech - Celine Haliouacelinehh.com
• Patrick Collison (Stripe CEO) - Craft, Beauty, & The Future of Paymentsdwarkeshpatel.com
• Curious cases of financial engineering in biotechowlposting.com
• Early-Stage Biotech Value Creation: The Roles of Equity and Partnershipsleadershipandbiotechnology.blogspot.com
• AI Versus Eroom's Lawsubstack.com
• Interview: Patrick Collison, co-founder and CEO of Stripenoahpinion.substack.com
• Power in the Age of Intelligencenotboring.co
• Rebuild Biotech for the AI Era | Benchlingbenchling.com
• APIs All the Way Down - Not Boring by Packy McCormicknotboring.co